07:00 , Apr 20, 2015 |  BC Week In Review  |  Clinical News

Nefecon: Phase IIb data

The double-blind, European Phase IIb NEFIGAN trial in more than 150 patients with primary IgA nephropathy at risk of developing end-stage renal disease (ESRD) was stopped early after a planned interim analysis by a DSMB...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Archimedes Pharma, Kyowa Hakko Kirin deal

Kyowa’s ProStrakan Group plc subsidiary completed its acquisition of Archimedes from life science investor Novo A/S for L230 million ($384.9 million) in cash (see BioCentury, July 14). Archimedes Pharma Ltd. , Reading, U.K.   Kyowa...
07:00 , Sep 1, 2014 |  BioCentury  |  Finance

Exiting Covagen

Terms of Johnson & Johnson 's takeout of Covagen AG are undisclosed, but the antibody platform company's largest investor said the deal is likely one of the biggest this year in terms of both size...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Kyowa Hakko Kirin Co. Ltd, Archimedes Pharma deal

Kyowa’s ProStrakan Group plc subsidiary will acquire Archimedes from life science investor Novo A/S for L230 million ($394.4 million) in cash. Archimedes has technologies for nasal and oral drug delivery and markets products in the...
00:28 , Jul 12, 2014 |  BC Extra  |  Company News

Kyowa's ProStrakan subsidiary to acquire Archimedes

The ProStrakan Group plc subsidiary of Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) will acquire Archimedes Pharma Ltd. (Reading, U.K.) from Novo A/S for L230 million ($394.4 million) in cash. Archimedes has technologies for nasal and...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Clinical News

Nefecon: Completed Phase IIb enrollment

Pharmalink completed enrollment of 90 patients with primary IgA nephropathy in the double-blind, placebo-controlled, pivotal, European Phase IIb NEFIGAN trial evaluating 8 and 16 mg Nefecon daily for 9 months. The company plans to seek...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Company News

Depomed sales and marketing update

Depomed launched Lazanda fentanyl nasal spray in the U.S. to manage pain and the Signature Support Program. Depomed said the Signature Support Program streamlines patient access to Lazanda and offers several services, including reimbursement assistance...
07:00 , Aug 5, 2013 |  BC Week In Review  |  Company News

Archimedes, Depomed sales and marketing update

Archimedes granted Depomed rights in the U.S. and Canada to pain drug Lazanda fentanyl nasal spray for $4 million in cash. Archimedes is eligible for up to $16 million in sales milestones and royalties. Lazanda...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Orexo management update

Orexo AB (SSE:ORX), Uppsala, Sweden   Business: Neurology, Inflammation, Drug delivery   Hired: Robert DeLuca as president of Orexo's Orexo US Inc. subsidiary, formerly chief commercial officer of Archimedes Pharma Ltd.  ...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

LigoCyte Pharmaceuticals, Takeda deal

Takeda will acquire LigoCyte for $60 million up front, plus potential milestones. LigoCyte's lead product is a norovirus VLP intranasal vaccine in Phase I/II testing to prevent norovirus gastroenteritis. The product is a dry powder...